Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
about
Cancer-Associated Myeloid Regulatory CellsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Microglia mediate postoperative hippocampal inflammation and cognitive decline in mice.The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomasColony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.The Basis of OncoimmunologyGlioblastoma: Defining Tumor Niches.Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Elimination of microglia improves cognitive function following cranial irradiationHuman breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation.Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor gradeThe contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Developing immunotherapeutic strategies to target brain tumors.The Promise of Targeting Macrophages in Cancer Therapy.Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage.Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.Tumour-associated macrophages as treatment targets in oncology.Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity.The Microenvironmental Landscape of Brain Tumors.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.Tumor-Associated Macrophages as Target for Antitumor Therapy.Microenvironmental regulation of tumour angiogenesis.Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and ImmunotherapiesInhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development.Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation.Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.A Survey of the Neuro-Oncology Landscape.Immunotherapy for brain tumors: understanding early successes and limitations.Advances in immunotherapeutic research for glioma therapy.When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.Immunotherapies for malignant glioma.CSF-1R Inhibitor Development: Current Clinical Status.Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.
P2860
Q26750382-D311E417-6F73-4244-A6D2-02071E9FE20FQ28078539-D6148197-04A1-4667-AA7F-CDD28AFCFF69Q30843381-FEBD03C0-015E-41C0-B974-28A4E07A2540Q33744491-0E1B6294-B60A-4808-A907-42776C879A6FQ33912938-87009D9C-DB66-4A9E-9C4C-0809471B8FFFQ36162776-EF872C09-77C4-49A5-89D2-D88EBD46D2EFQ36678851-8A4B7F6E-339A-49ED-93BB-4B216918EA3BQ36796616-F1996808-B72E-477B-890A-626A352B8C24Q37073330-ECB8E70C-C5CA-4058-9D18-3B50DA8B8161Q37079141-503B2F38-237E-4E04-B36B-FBCD9CEB32C0Q37168968-DEFA1249-B570-4FE7-8875-81864424F7D1Q37262555-FC3D47D5-0591-4318-97F7-6ADCA4EC8D8CQ37576290-1C8F6B7D-BDEF-428D-9F3C-F6BECFCC9B5FQ38675589-B7FB9A41-56B9-4559-A485-1EAB11EED62EQ38851464-75B0285C-71F8-47BC-B64D-D455957B8511Q38877313-74F687CD-3C93-429D-BF66-EECF8925E271Q38880272-A77F7BC2-A84F-468F-8770-3B69FF901CB1Q39022841-31DA8A98-2597-47D1-BF10-EA18E57FD419Q39100693-3640F8D3-5C8B-4822-AED8-5B71D108723EQ39144794-6B73436E-4115-461A-8898-59F06E8A1582Q39178065-3707ABE2-F56B-4079-90AD-09F1B2805341Q39196377-E56B16A1-D3C1-4504-A145-AB423F8C4E5FQ39403895-D600DDE3-CD99-49A6-9D82-D62951F883E0Q39433862-E6534052-89E8-4C85-9C33-85CEDA673BE8Q40082476-3159E2DB-751C-42D8-955D-EFAF0EE9A9D2Q41011622-1993C278-3F4A-485C-90DA-3BCA5CF0741BQ43290383-9CA7EB23-F585-4BB3-8047-C9A90C80B547Q47099432-87D6E296-8761-43EA-83A7-40995364E2FEQ47141786-7981A368-37D6-426D-A3E2-04BC53ED3111Q47270219-1CB0E17B-2C9A-4E48-96DB-D886358D6419Q47404669-3927FD1E-A66B-4ED3-8B09-676CE729ACE2Q47431855-CCBB08A0-4F93-434F-A74D-1C01996A9AA3Q47555498-435CE3EA-5A68-4EC5-906E-EE2E07F5EF98Q47569046-8818061F-16B6-4B16-B86C-6EA051FFF6FBQ47826206-EAFAB284-A34F-4542-8D12-E4B1D1AFB370Q47851037-93F4CA51-3139-4D28-8A57-0133F183DCB3Q47915209-EB50E4B7-C3B6-4D6B-A825-DE6C54404CC6Q47963731-7A27854A-722A-4454-AD9C-7525D56CB536Q48290538-D9C88E9D-AD11-4E8B-8DF0-2C78F1D475A8Q48293592-412AE672-7364-4E18-9388-E408D1E86FFE
P2860
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Orally administered colony sti ...... als Consortium phase II study.
@ast
Orally administered colony sti ...... als Consortium phase II study.
@en
type
label
Orally administered colony sti ...... als Consortium phase II study.
@ast
Orally administered colony sti ...... als Consortium phase II study.
@en
prefLabel
Orally administered colony sti ...... als Consortium phase II study.
@ast
Orally administered colony sti ...... als Consortium phase II study.
@en
P2093
P2860
P356
P1433
P1476
Orally administered colony sti ...... als Consortium phase II study.
@en
P2093
Adhirai Marimuthu
Annette M Molinaro
Antonio M Omuro
Arie Perry
Henry H Hsu
Howard Colman
Jason Huse
Joanna Phillips
John F De Groot
Keith B Nolop
P2860
P304
P356
10.1093/NEUONC/NOV245
P50
P577
2015-10-08T00:00:00Z